These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18402015)

  • 1. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure.
    Othersen JB; Maize JC; Woolson RF; Budisavljevic MN
    Nephrol Dial Transplant; 2007 Nov; 22(11):3179-85. PubMed ID: 17890246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.
    Marckmann P; Skov L; Rossen K; Dupont A; Damholt MB; Heaf JG; Thomsen HS
    J Am Soc Nephrol; 2006 Sep; 17(9):2359-62. PubMed ID: 16885403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T; Prischl FC
    Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 9. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A; Fogel M; Cowper SE
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
    Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
    Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 19. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA; Rodby RA
    Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.